About MS  > MS news and research  > Drugs  > RPC1063
About MS

What is MS?

MS symptoms

Managing your MS

Effects of MS

MS news and research

Bacteria and viruses

Biomarkers and microRNA

CCSVI

Cognition

Diet

Drugs

Ampyra (Fampyra)

ATL1102

Aubagio

Betaferon (Betaseron)

Cannabis and cannabinoids

Copaxone, Glatopa and glatiramer acetate

Emerging therapies

Gilenya

Low dose naltrexone

Lemtrada (alemtuzumab)

Masitinib

MIS416

MN-166 (ibudilast)

Nerventra® (laquinimod)

Ocrelizumab

Plegridy (peginterferon beta-1a)

RPC1063

Sativex

Statins

Tcelna

Tecfidera

Tysabri

Zenapax (daclizumab)

Endo-parasites and helpful organisms

Environmental factors

Ethnic groups, geographical regions and MS

Exercise

Genetics

Hormones

Immune cells

Inflammation, lesions & 'black holes'

Medical imaging

MS Symptoms research

Multiple Sclerosis (etiology)

Myelin

Nerves, brain cells and spinal cord

Paediatric MS

Pain

Potential viral causes

Quality of life

Retroviruses

Sex and MS

Stem cells

Technology

Types of MS

Vaccinations

Vitamin D

World MS Day

News and research archive

Other support

Donate with JustGiving

Latest Tweets

RPC1063

 

SUNBEAM phase 3 trial for relapsing multiple sclerosis launched(21/01/15)

Biopharmaceutical company Receptos, Inc. has enrolled the first participant with relapsing multiple sclerosis (RMS) in its SUNBEAM phase 3 trial, which will evaluate the potential therapy RPC1063 in patients who have the multiple sclerosis. The company’s phase 3 RADIANCE trial, also involving RMS patients, had already been initiated, which means that Receptos may be able to finish its clinical development program for multiple sclerosis by 2017, according to the company’s press release.

RPC1063 is a novel, oral, once daily, selective sphingosine 1-phosphate 1 and 5 receptor modulator being developed by Receptos for the treatment of autoimmune indications such as RMS, but also ulcerative colitis (UC) as well. “Our initiation of the SUNBEAM trial represents another major corporate milestone for Receptos, and positions RPC1063 as the potential next-to-market oral agent for the treatment of relapsing multiple sclerosis,” said the president and chief executive officer of Receptos, Faheem Hasnain.

Both the SUNBEAM and RADIANCE trials are randomised, double-blind studies that will include 1,200 RMS patients, and are designed to compare 0.5 mg and 1.0 mg doses of RPC1063 with interferon beta-1a (Avonex). In addition, the trials aim to evaluate RPC1063’s superiority in comparison with Avonex regarding the decrease of the annualised relapse rate following either one or two years of therapy. Both of the phase 3 trials are taking place under Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA).

The RPC1063 therapy had already been demonstrated to be promising for treatment of MS, as it met the primary endpoint of reduction in MRI brain lesion activity and secondary endpoints measuring effects of other MRI parameters in its phase 2 trials, which were announced last summer. In addition, researchers were also able to trace a consistent safety profile. Receptos presented the findings at the largest meeting dedicated to MS to date, the joint meeting of the Americas Committee for Treatment and Research In Multiple Sclerosis (ACTRIMS) and the European Committee for Treatment and Research In Multiple Sclerosis (ECTRIMS).

“Following our recent positive Phase 2 results in ulcerative colitis, we also plan to initiate a Phase 3 program for RPC1063 in inflammatory bowel disease in 2015. We believe that this drug candidate represents a potential franchise in immunology, and we continue to explore opportunities in other therapeutic indications where there is strong scientific rationale,” added the president and CEO of Receptos.

After having announced that they were looking for RMS patients for the SUNBEAM and RADIANCE trials at the end of last year, the company is also going to assess the RPC1063 therapy in inflammatory bowel disease (IBD) patients in its TOUCHSTONE phase 3 trial, which includes patients who suffer from UC, and a phase 2 trial in patients with Crohn’s disease. Both of the trials are scheduled to begin this year, and are based on the encouraging results obtained by the company in its prior studies of the medication with IBD.

Source: Multiple Sclerosis News Today © BioNews-tx.com 2015 (21/01/15)